

# 1 COVID-19: Spatial Analysis of Hospital Case-Fatality 2 Rate in France

3

4 Marc Souris<sup>1</sup>

5 <sup>1</sup>UMR Unité des Virus Émergents (UVE Aix-Marseille Univ-IRD 190-Inserm 1207-IHU  
6 Méditerranée Infection), Marseille 13005 France. Email: [marc.souris@ird.fr](mailto:marc.souris@ird.fr)

7 Jean-Paul Gonzalez<sup>2</sup>

8 <sup>2</sup>School of Medicine, Georgetown University, Department of Microbiology & Immunology,  
9 Washington, DC 20057 USA. Commonwealth Trade Partners Inc. Centaurus Biotech LLC.  
10 Email: [Jean.Paul.Gonzalez@georgetown.edu](mailto:Jean.Paul.Gonzalez@georgetown.edu)

11

12 Corresponding author: Marc Souris, [marc.souris@ird.fr](mailto:marc.souris@ird.fr)

13 Keyword: COVID-19, Case-Fatality Ratio, standardization, spatial analysis, SLR,  
14 SMR.

## 15 Abstract

16 When the population risk factors and reporting systems are similar, the  
17 assessment of the case-fatality (or lethality) rate (ratio of cases to deaths) represents  
18 a perfect tool for analyzing, understanding and improving the overall efficiency of the  
19 health system.

20 The objective of this article is to estimate the influence of the hospital care system  
21 on lethality in metropolitan France during the inception of the COVID-19 epidemic, by  
22 analyzing the spatial variability of the hospital case-fatality rate between French  
23 districts.

24 The results show that the higher case-fatality rates observed in certain districts are  
25 mostly related to the level of morbidity in the district, therefore to the overwhelming of  
26 the healthcare systems during the acute phases of the epidemic. However, the  
27 magnitude of this increase of case-fatality rate represents less than 10 per cent of the  
28 average case-fatality rate and cannot explain the magnitude of the variations in case-  
29 fatality rate reported by country by international organizations or information sites.  
30 These differences can only be explained by the systems for reporting cases and  
31 deaths, which, indeed, vary greatly from country to country, and not attributed to the  
32 care or treatment of patients, even during hospital stress due to epidemic peaks.

## 33 Introduction

34 Since the beginning of the epidemic, the case-fatality rate of COVID-19 and the  
35 differences between countries have been the subject of many questions about national  
36 pandemic response policies and patient treatment. Most studies on the lethality of

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

37 COVID-19 seek to estimate the true lethality of the disease, an issue that has been  
38 addressed since the beginning of the epidemic [MOR 20] [RIN 20] [SPY 20] [BAU 20].

39 The case-fatality rate (or lethality rate) is the ratio between the number of closed  
40 cases (i.e. recovered or dead) and the number of deaths due to the disease, it is  
41 estimated by the healthcare system based on the reporting of these two values. The  
42 case-fatality rate should not be confused with the mortality rate, which is the ratio of  
43 the number of deaths to the total population, or also with the morbidity rate, which is  
44 the ratio of the number of cases to the total population. Mortality and morbidity rates  
45 depend on the extent of disease in a population, unlike case-fatality rates, which are  
46 normally calculated independently of the number of infected persons [POR 08].

47 The case-fatality rate of a disease in a population is an index of severity of the  
48 disease in that population, and of the capacity of the healthcare system to reduce  
49 mortality. In principle, this allows to compare the effectiveness of healthcare systems  
50 across regions or countries.

51 The aim of this article is to analyze the effectiveness of the healthcare system in  
52 France in the context of the COVID-19 epidemic. Based on spatial differences in  
53 lethality, this study ultimately show that the case-fatality rates published by the  
54 international agency by country (May 2020) do not allow to compared the country one  
55 to the others.

56 Lethality depends on the intrinsic virulence of the virus but, unlike morbidity, it does  
57 not depend on its contagiousness. Virulence comes from the reproductive capacity of  
58 the virus in the cell, its capacity for cellular degradation, and its ability to induce or not  
59 an innate or specific immune response. Virulence is of purely biological origin and once  
60 the virus has entered the target cell where it will cause its pathogenic effect does no  
61 longer depends on environmental conditions outside the host. Virulence is independent  
62 of the host population, but may change over time and space if there is a risk of natural  
63 mutation/selection of the pathogen. Contagiousness characterizes the biological  
64 capacity of the virus to reach the target cell system of its host, and the ability to be  
65 transmitted from one individual to another. The efficiency of transmission depends  
66 largely on environmental conditions (e.g., climate, urbanization, population density,  
67 mobility), which can vary greatly from one country to another.

68 In addition to the virulence of the virus, the case-fatality rate depends on biological  
69 risk factors and on population vulnerability (age structure, genetic factors, prevalence  
70 of co-morbidities, healthcare accessibility, etc.) as well as other factors related to the  
71 health system (equipment, capacity, staff, management, care of patients, effectiveness  
72 of therapies, patient management in a critical phase of the disease), and factors related  
73 to the detection and registration system for cases and deaths (clinical cases definition,  
74 detection, surveillance systems, case and death reporting). The evaluation of the case-  
75 fatality rate normally requires the detection and counting of all infected persons,  
76 irrespective of their level of symptoms (i.e. disease severity).

77 When the population risk factors and reporting systems are identical, case-fatality  
78 rate evaluation represents an excellent tool for analyzing, understanding and improving  
79 the overall performance of the health system, particularly at the level of hospital units.

80 Studying the magnitude of differences in case-fatality rates between units also makes  
81 it possible to assess the impact of the quality of the health system on case-fatality.

82 There are large differences in the case-fatality rates of COVID-19 published by  
83 country (Table 1) or calculated directly from WHO data. These rates vary considerably,  
84 from less than 0.02 (Thailand, Australia, Chile) to more than 0.15 (France, Belgium,  
85 UK), with a mean at 0.04 and a standard deviation of 0.045 (WHO, May 8, 2020, Figure  
86 1).


Country	Case-Fatality rate (%) <sup>*</sup>	Population > 65-year-old (%) <sup>**</sup>	Hospital bed number <sup>***</sup>
France	19.00	20.02	621
Belgium	16.42	18.80	623
UK	14.94	18.40	273
Italy	13.84	22.75	331
Netherlands	12.59	19.20	466
Sweden	12.29	20.10	254
Spain	11.73	19.38	297
Iran	6.31	6.18	150
USA	5.40	15.80	290
Greece	5.52	21.65	424
China	5.50	10.92	420
Switzerland	5.01	18.62	470
Germany	4.28	21.46	823
Portugal	4.15	21.95	332
Austria	3.88	19.02	760
Tanzania	3.75	2.60	70
Japan	3.56	27.58	1340
India	3.36	6.18	70
Czech Republic	3.28	19.42	645
Turkey	2.72	8.48	270
Norway	2.62	17.05	390
Uruguay	2.53	14.81	280
South Korea	2.36	14.42	1150
Thailand	1.83	11.90	210
Slovakia	1.74	15.63	579
Australia	1.41	15.65	380
Chile	1.21	11.53	220

87 Table 1: Case-fatality rates and characteristics of vulnerability to COVID-19

88 Caption: \*Lethality rate for Covid-19 reported among selected countries from WHO, as for  
89 May 8, 2020 [WHO 20]; \*\*population percentage over 65-year-old by World Bank, 2016;  
90 \*\*\*Hospital beds per 100,000 people by World Bank, 2013, Eurostat, 2014

91

92



93  
94  
95

Figure 1. Distribution of case-fatality rates calculated by country, based on case and death data from WHO (WHO, May 8, 2020).

96  
97  
98  
99  
100  
101  
102  
103

In Europe, the characteristics of populations (in terms of risk factor for COVID-19) and health systems are quite similar, but the definition, detection and reporting of cases and causes of death can differ greatly from one country to another. Some countries conducted significantly more detection tests and hospitalizations than others (Table 2), resulting in differences in the protocols for patient management. The rate of testing performed (policy) and mortality rates (reporting) vary mainly according to the geographical extent of the epidemic within each country.

Country	rtPCR Test number per 1,000*	Morbidity rate (cases per million)	Mortality rate (death per million)
Belgium	44	4488	735
Spain	41	5494	558
Italy	39	3570	495
Germany	33	2022	88
Australia	29	271	4
United States	25	3906	232
United Kingdom	22	3045	451
France	21	2678	398
Turkey	15	1586	43
Netherlands	14	2438	309
South Korea	12	211	5
Iran	6	1246	78
Japan	1.5	122	4.5
India	1	41	1.4
Indonesia	0.5	48	3.5

105 Table 2: SARS-Cov-2 detection, COVID-19 morbidity and mortality rates by selected country.  
 106 Source: Worldometer, May 8, 2020

107 The virulence of the COVID-19 pathogen (SARS-CoV-2 virus) is assumed to be  
 108 identical in all countries. In order to compare case-fatality rates across regions or  
 109 countries (and thus analyze the effectiveness of healthcare systems), it is necessary,  
 110 when calculating rates, to standardize population-related risk factors and to use the  
 111 same definitions and enumeration methods to record cases and deaths. This is not the  
 112 case for the current pandemic and discrepancies exist among the country systems.

113 The objective of this article is not to estimate the actual lethality of COVID-19 in  
 114 France based on the rates published by the health authorities, but to estimate the  
 115 influence of the healthcare system on lethality by analyzing the spatial variability of the  
 116 hospital case-fatality rate (confirmed hospitalized cases and hospital deaths) in  
 117 metropolitan France between districts (i.e. French départements). This analysis,  
 118 limited to metropolitan France, makes it possible while it remains within the framework  
 119 of the same system for defining and counting cases and deaths. We thus assume that  
 120 this system of definition and enumeration was identical throughout France during the  
 121 period (19 March to 8 May) corresponding to the first wave (inception) of the COVID-  
 122 19 epidemic in France. Therefore the study focuses on the extent of spatial differences  
 123 in the case-fatality rate in metropolitan France, and enable to highlight the relative  
 124 differences between districts, as well as to analyze the causes independently of the  
 125 system of definition and enumeration of cases and deaths, and also independently of  
 126 the main biological risk factor of severity (age) after standardization on this factor.

127 Estimating the variability of the case-fatality rate attributable exclusively to hospital  
 128 care of patients will then allow us to compare the case-fatality rate observed in  
 129 metropolitan France with the one calculated for other countries. It will allow us to  
 130 estimate whether the variability of the case-fatality rate due to the management of

131 patients in the acute epidemic phase can exclusively explain the significant differences  
132 in case-fatality rates observed between countries.

## 133 Data and Methods

### 134 Data

135 This study is based on daily hospitalization and death declaration data by district  
136 in France and is accessible on the “Santé Publique France” website.  
137 ([www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-](http://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19)  
138 19) from March 19 to May 8, 2020, corresponding to 50 days lockdown (i.e. quarantine)  
139 and the spread of the COVID-19 epidemic in France. We also obtain demographic data  
140 by districts (source: population by age, INSEE, 2020), as well as data on the  
141 distribution of hospitalized cases according to age group (10-year age group) (Santé  
142 Publique France). This analysis was carried out on the 96 districts of metropolitan  
143 France (Figure 2), while the French overseas districts and territories were excluded  
144 from the analysis for reasons of spatial analysis and mapping. The data were  
145 integrated into a geographic information system (SavGIS, [ww.savgis.org](http://ww.savgis.org)) for analysis  
146 and mapping.




Figure 2. The 96 Districts of Metropolitan France

147  
148

149 Focusing only on confirmed hospitalized cases and deaths in hospital, the case-  
150 fatality rates calculated in this article for France refer to the hospital case-fatality rates  
151 and do not represent the absolute national case-fatality that should include all positive  
152 cases and deaths related to COVID-19. Given the estimated high number of non-  
153 severe and asymptomatic forms (which a fortiori do not cause deaths) - it is estimated  
154 that only 2.6% of infected persons were hospitalized [SAL 20] - this overall lethality is  
155 necessarily much lower than hospital lethality, but it will be accurately calculated only  
156 at the end of the epidemic when the total number of positive cases (i.e. seroprevalence  
157 survey) will be available and the total number of deaths outside hospital due to COVID-  
158 19 will be accurately assessed.

159 All identified and hospitalized cases were tested positive (by rtPCR). All deaths  
160 counted were COVID-19 associated. As of May 8, 2020, not all hospitalized cases are  
161 closed since the epidemic is still ongoing: deaths counted at the beginning of the study  
162 period correspond to cases hospitalized but were not included in the study, and cases  
163 counted at the end of the period were not closed and no deaths from these cases were  
164 included in the study.

## 165 Methods

### 166 Age standardization

167 Since age is a major risk factor for death, age standardization eliminates  
168 differences in hospitalization rates, mortality rates, or case-fatality rates between  
169 districts due to differences in the age structure of the population of the districts, We  
170 performed an indirect standardization by calculating the rate (hospitalization rate and  
171 hospital rate) per ten-year age group for the whole of France. Then also lethality rate  
172 for the whole of France was calculated but excluding areas that have been under  
173 hospital stress (Ile-de-France and Grand-Est). This was done in order to evaluate  
174 hospital case-fatality rates per age group independently of possible excess mortality  
175 due to the saturation of healthcare systems in certain districts. Classically,  $E_i$  (number  
176 of deaths expected in district  $i$ ) is the sum over the different age groups of the district's  
177 population in the age group multiplied by the hospital case-fatality rate of the age  
178 group:

$$179 \quad E_i = \sum_{\text{age class } a} P_a \times T_a$$

180 where  $P_a$  is the population of the age group "a" and  $T_a$  is the hospital case-fatality  
181 rate of the age group calculated over all districts.

### 182 Standardized case-fatality rate

183 The Standardized Lethality Ratio (SLR) is equal to the ratio between the observed  
184 death toll  $O_i$  and the expected death toll  $E_i$ . The standardized hospital case-fatality  
185 rate  $LS_i$  for each district is equal to the average rate for France multiplied by the  
186 district's SLR. The significance of the SLR ( $H_0$ : SLR=1, no statistically significant over  
187 - or under-fatality compared to the expected value) is evaluated for each district by a  
188 Breslow & Day test [SOU 19] in order to account for the statistical significance of the  
189 differences in these ratios between districts. In order to take into account the problem  
190 of multiple testing [MIL 96] when the null hypothesis concerns the whole territory ("is  
191 there a district for which the  $H_0$  hypothesis is rejected?"), the risk of error was set at  
192 0.0005 in order to apply a Bonferonni correction (which is very conservative when data  
193 is spatially autocorrelated). When the study is conducted for a single district ("Is the  
194 SLR for this district different from 1?"), the risk of error is set at 0.05. All tests are  
195 bilateral.

### 196 Cartography

197 The values of morbidity rates, mortality rates, non-standardized case-fatality rates,  
198 SLRs and their significance were mapped by districts. In order to map case-fatality  
199 rates independently of the rate calculation variability, due to differences in  
200 hospitalization numbers between districts, rates adjusted with empirical Bayesian  
201 estimator (EBE) were calculated [SOU 19]. All statistical processing, mapping and  
202 space-time animations were carried out using the SavGIS geographic information  
203 system.

### 204 Study of statistical correlations



205 In order to estimate whether possible congestion in the healthcare system  
 206 influenced hospital case-fatality rate, we studied the correlations between  
 207 hospitalization and hospital lethality in a global manner over the entire period. Inpatient  
 208 severity was estimated using the ICU rate (number of patients in intensive care/number  
 209 of inpatients).

## 210 Results


211 For the whole of France (data from 19 March to 8 May 2020), the hospital case-  
 212 fatality rate was 0.174. The average hospital case-fatality rates by age group, used in  
 213 indirect standardization, was calculated from French Public Health data published on  
 214 8 May 2020 (Table 3).

Age class	Population (%)	Hospitalization					
		Hospitalized		Death		Case-Fatality Rate (whole country)	Case-fatality Rate without 11 and 44 regions
		Total	%	Total	%		
0-9	11.43	617	0.65	2	0.01	0.0032	0
10-19	12.27	463	0.49	3	0.02	0.0065	0
20-29	11.15	2253	2.4	19	0.11	0.0084	0.0051
30-39	12.36	4325	4.5	72	0.44	0.0166	0.0088
40-49	12.80	7001	7.4	203	1.24	0.0290	0.0183
50-59	13.10	12130	12.9	747	4.56	0.0616	0.0435
60-69	12.01	16115	17.1	1934	11.81	0.1200	0.0988
70-79	8.57	18812	20.0	3723	22.73	0.1979	0.1666
80-89	4.91	21625	22.9	6192	37.80	0.2863	0.2688
90+	1.38	10897	11.5	3485	21.28	0.3198	0.3047
All ages	1	94238	1	16380	1	0.1738	0.1597

215 Table 3. Hospitalization, mortality and case-fatality rates by age group in metropolitan France  
 216 (2020).

217 The epidemic in France (data from 19 March to 8 May 2020) presents a very  
 218 uneven spatial distribution of hospitalizations. It has developed throughout the country  
 219 at low level, with a mean hospitalization rate of 1.27 per 1,000 (median at 0.88) and a  
 220 standard deviation of 1.03, except in some regions where transmission has been much  
 221 more active, such as the Ile-de-France region (mean hospitalization rate 3.01 per  
 222 1,000), or the Grand-Est region (mean hospitalization rate 3.2 per 1,000). The mean  
 223 hospitalization rate varies from 0.19 per 1,000 (Tarn-et-Garonne) to 4.75 (Territoire de  
 224 Belfort) (Figure 3).

225 The hospital mortality rate (not age-standardized) has the same spatial distribution.  
 226 It varies from 0.01 per 1,000 (Tarn-et-Garonne) to 1.13 per 1,000 (Territoire de Belfort),  
 227 with a mean of 0.21 (median 0.12) and a standard deviation of 0.21.



230 Figure 3: Hospitalization rate (a) and hospital mortality rate (per 1000 inhabitants) (b) for  
231 COVID-19 in metropolitan France for the period March 19 to May 8, 2020.

232 A cartographic representation by cartogram shows the relative differences in the  
233 circulation of the disease in certain districts of the Grand-Est and Ile-De-France regions  
234 and the rest of France (Figure 4).





Figure 4. Cartogram of the standardized hospitalization rate for COVID-19 in France from March 19 to May 8, 2020.

Caption: The geometry of the districts in France is shown in the lower left corner.


239 The observed gross hospital case-fatality rate by district showed a mean of 0.153  
 240 with a standard deviation of 0.045. It varies between 0.046 (Ariège) and 0.258  
 241 (Vosges). Without the Ile-de-France and Grand-Est regions, the mean gross case-  
 242 fatality rate per district is 0.149 with a standard deviation of 0.048 (figure 5).



243  
 244

245 Figure 5: Case-fatality rate (a) and case-fatality rate adjusted by empirical Bayesian  
 246 estimator (b) for the COVID-19 epidemic in France from 19 March to 8 May 2020


247 Case-fatality rates have evolved over the period studied. Here we represent non-  
 248 standardized rates calculated for three periods: March 19 to 31; April 1 to 12; April 13  
 249 to 25. Rates are calculated with a 12-day time lag between cases and deaths (Figure  
 250 6).



251  
 252

253 Figure 6: Calculated case-fatality rates by 13-day period.

253 The SLR per district is between 0.25 (Ariège) and 1.48 (Vosges), with the mean at  
 254 0.88 and the median at 0.90. If the Ile-De-France and Grand-Est regions are excluded  
 255 from the calculation of age-specific case-fatality rates, the SLR is between 0.28 and  
 256 1.67, with the mean at 0.99 and the median at 1 (Figure 7). In the following, we will  
 257 consider only the SLRs calculated with age-specific case-fatality rates that do not take  
 258 into account the Ile-De-France and Grand-Est regions.




259  
260

Figure 7. Standardized Lethality Ratio

261 The spatial distribution of standardized morbidity rate (hospitalized cases) shows  
262 a significant spatial autocorrelation (Moran index: 1.54,  $p$ -value  $< 10^{-6}$ ), and this is  
263 expected for an infectious disease. The case-fatality rate shows also significant spatial  
264 autocorrelation (Moran index: 0.29,  $p$ -value  $< 0.000007$ ), and this is no expected. The  
265 analysis of the clusters clearly shows a clustering of high case-fatality rate values in  
266 regions of high morbidity (particularly the Grand-Est), and shows some cases of  
267 districts with high case-fatality rate values isolated in areas with low rates.

268 The Breslow & Day significance test shows districts where the SLR is statistically  
269 significantly different from 1, corresponding to districts with abnormally high (SLR  $> 1$ ,  
270 red) or abnormally low (SLR  $< 1$ , green) case-fatality rates. The individual significance  
271 threshold is set at 0.05, and for all districts at 0.0005 to account for multi-testing (Figure  
272 8).



275 Figure 8. Geographical units (districts) with SLR significance.

276 Legend: p-value < 0.05 (a), p-value < 0.0005 (b)

277 There is a correlation between the standardized hospitalization rate and the  
278 standardized case-fatality rate (Bravais-Pearson index=0.40) (Figure 9), a correlation  
279 which increases (0.48) if we limit the calculation to districts whose SLR is significantly  
280 different from 1 (p-value < 0.05).




Figure 9. Correlation between Hospitalization rate and Case-fatality rate during the COVID-19 epidemic in France for the period of time between March 19 to May 8, 2020.


To illustrate the increase of case-fatality rate with hospitalization rate, Table 4 gives the mean of the standardized case-fatality rate over the districts according to their standardized hospitalization rate. The average case-fatality rate varies from 0.134 for

287 districts with a low hospitalization rate (less than 0.5 per 1000) to 0.152 for all districts.  
 288 If only districts with high hospitalization rates (above 2 per 1000) are considered, the  
 289 average case-fatality rate is 0.183. For the eight districts with the highest  
 290 hospitalization rates (> 3 per 1,000), and considered as district under hospital stress,  
 291 the average case-fatality rate is 0.191 (Meuse, Moselle, Seine-St-Denis, Hauts-de-  
 292 Seine, Paris, Val-de-Marne, Haut-Rhin, Territoire de Belfort), while it is 0.149 for all  
 293 other districts.

Hospitalization rate (per 1000)	Districts number	Case-fatality rate (mean)	p-value of T-test with international mean of case-fatality rate
< 0.5	31	0.134	< 10 <sup>-6</sup>
< 1	59	0.138	< 10 <sup>-6</sup>
< 1.5	72	0.142	< 10 <sup>-6</sup>
< 2	80	0.146	< 10 <sup>-6</sup>
< 2.5	86	0.147	< 10 <sup>-6</sup>
< 3	89	0.149	< 10 <sup>-6</sup>
< 3.5	90	0.149	< 10 <sup>-6</sup>
< 4	93	0.150	< 10 <sup>-6</sup>
all	96	0.152	< 10 <sup>-6</sup>

294 Table 4. Average case-fatality rate as a function of hospitalization rate during the COVID-19  
 295 epidemic in France for the period of time between March 19 to May 8, 2020.


296 The mapping of the hospitalization rate and the hospital mortality rate with the SLR  
 297 shows the spatial correspondence of these values (Figure 10).



298  
 299  
 300 Figure 10. SLR (symbols) and Hospitalization rate (a) and case-fatality rate (b) during the  
 301 COVID-19 epidemic in France for the period of time between March 19 to May 8, 2020.


302 A typology combining hospitalization rates and case-fatality rates is proposed: low  
 303 rates (values below the mean by less than one standard deviation), high rates (values

304 above the mean by more than one standard deviation), so as to represent four classes  
305 (low-low, low-high, high-low, high-high). The hatched areas represent those for which  
306 the SLR is not significant ( $p$ -value > 0.05) (Figure 11).



307  
308 Figure 11. Combination of standardized hospitalization and case-fatality rates in four classes.

309 The ratio between the rate of patients in intensive care and the rate of  
310 hospitalization gives in principle an indication of the severity of the patients in hospital.  
311 This hospitalization rate and severity rate show a weak negative correlation ( $r=-0.22$ ),  
312 indicating a decrease in the intensive care rate when the hospitalization rate is high.  
313 This trend may be due to the saturation of intensive care units. The relationship  
314 between hospitalization and severity could also be interpreted as a decrease in less  
315 severe hospitalizations in order to be able to manage more severe cases when the  
316 healthcare system is overloaded, which would result in an increase in lethality.  
317 Nevertheless, in both cases, there is no correlation between the severity rate and the  
318 case-fatality rate ( $r=-0.1$ ), indicating that globally, the intensity of reanimation does not  
319 impact the case-fatality rate. Finally, the severity rate does not have a spatial  
320 distribution corresponding to the increase in the hospitalization rate (Figure 12).



321  
322  
323

Figure 12. Severity ratio during the COVID-19 epidemic in France for the period of time between March 19 to May 8, 2020.

## 324 Discussion

325 The standardized case-fatality rates (SLR) of the districts in France (0.04 for Tarn-  
326 et-Garonne to 0.26 for the Vosges district) remain in a ratio of 0.3 to 1.6 compared with  
327 the national average of 0.14, calculated by excluding districts under stress in order not  
328 to take account of possible saturation of the care systems. The relationships between  
329 morbidity rates and standardized case-fatality rates in France show a correlation  
330 between these two indices, the average case-fatality rate for all districts being about  
331 15% higher than the average rate calculated in the 20% of districts with the lowest  
332 hospitalization rates. It is therefore very likely that the increase in hospital tension over  
333 the period under consideration has increased the hospital case-fatality rate: for the 20  
334 districts with the highest hospitalization rates (essentially located in the Grand-Est and  
335 Ile-De-France regions), the average case-fatality rate is 20 per cent higher than the  
336 average for all districts, and 25 per cent higher than the average for all other districts  
337 alone. It can be concluded that hospital case-fatality rates have increased the national  
338 average case-fatality rate by district from 0.145 to 0.153. It can therefore be estimated  
339 that 2,425 deaths (out of the 16,732 deaths due to COVID-19 in hospital in France from  
340 19 March to 8 May 2020, i.e. 15% of the total number of deaths) are due to the  
341 saturation of the health system in the Grand-Est and Ile-De-France regions.



342 There are clearly two risk profiles: 1/ the districts where a high rate of  
343 hospitalization is coupled with a high case-fatality rate, and 2/ the districts where a low  
344 rate of hospitalization is coupled with a high case-fatality rate. The first category  
345 probably results from an increase of lethality due to saturation of the health care  
346 system. The second category is probably linked to the opposite phenomenon: a low  
347 hospital case-fatality rate which would have led to an increase in lethality due to a local  
348 lack of healthcare access (e.g. medical deserts, poor hospital lethality preparation). It  
349 has also been noted that all these late districts are located in essentially rural areas.  
350 Some districts in the south of France have both a very low rate of hospitalization and  
351 a very low case-fatality rate (Gironde, Dordogne, Gers, Pyrénées Orientales), as a  
352 result of the low circulation of the virus and the effective response of the health system.  
353 Another particular case, is the one of the Bouches-du-Rhône, which appears with a  
354 high hospitalization rate (1.96 per 1,000, for a national average of 1.27) and a low  
355 case-fatality rate (0.11 for the Bouches-du-Rhône for a national average per district of  
356 0.15). This situation could be due to a medical policy of more active screening and  
357 earlier hospitalization of the infected in the district, particularly in Marseille metropolitan  
358 area. The high value of the hospitalization rate would then be more the result of a non-  
359 severe treatment of the infected than of a more active circulation of the virus in the  
360 region, as for the lower hospitalization rates in neighboring districts (0.9 for Var, 0.56  
361 for Vaucluse, 0.52 for Gars, 0.86 for Alpes-de-Haute-Provence, 0.81 for Alpes-  
362 Maritimes, 0.68 for Hérault). However, patient severity profile (expressed as the ratio  
363 between the number of patients admitted to intensive care and the total number of  
364 patients hospitalized) is not particularly low in the Bouches-Du-Rhône (0.163 for a  
365 mean of 0.156 and a standard deviation of 0.06 for all the districts), and this  
366 hospitalization policy is therefore not proven to be the primary factor in the low  
367 observed case-fatality rate.

368 Time analysis shows that the case-fatality rate has decreased over time, globally  
369 and in almost all districts, showing an improvement in the management of severe  
370 patients during the epidemic. This decrease stabilized rapidly and no longer evolved  
371 in a steady manner. However, this result is limited by the difficulty of calculating a case-  
372 fatality rate on aggregated data over a short period of time, with eventual death  
373 occurring several days after hospitalization. We chose to delay the calculation of the  
374 number of deaths by 12 days compared to the calculation of the number of  
375 hospitalizations, since 85% of deaths occur on an average of 13 days after  
376 hospitalization [SAL 20].

377 WHO data from 219 countries (WHO 20) show a mean case-fatality rate of 0.041  
378 (median 0.029, standard deviation 0.045) with values between 0.31 (Nicaragua) and  
379 0.00 (for countries that did not report deaths, like Vietnam). A T-test shows that the  
380 French average is therefore very significantly higher than the world average ( $p$ -value  
381  $< 10^{-6}$ ). Even if we consider only the average case-fatality rate calculated only for the  
382 French districts with the lowest hospitalization rates (thus not causing saturation of the  
383 health care system), this average is still very significantly higher than the international  
384 average (and the rates of most European countries, such as Spain, 11.73, Greece,  
385 5.52, Germany, 4.28, etc.) (table 4). Taking into account the quality of the healthcare  
386 system in France (table 1), it can be concluded that the difference between the case-

387 fatality rate calculated for France and the case-fatality rates presented using  
388 international WHO data is highly probably the result of a difference in the registration  
389 of cases and/or deaths and not due to the quality of health care. These differences in  
390 the counting of cases and/or deaths may be due to the hospitalization and screening  
391 policy specific to each country as well as the ability or willingness to hospitalize more  
392 non-severe forms, to the differences in case definition, or to insufficient quality of the  
393 system for detecting and reporting cases and deaths.

## 394 Conclusion

395 This study shows that the higher case-fatality rates observed in France in certain  
396 districts during the first wave of the COVID-19 epidemic (data from 19 March to 8 May  
397 2020) are mostly linked to the level of morbidity in the district, and therefore to the  
398 congestion of the healthcare systems during the acute phases of the epidemic. When  
399 the hospitalization rate is low, high case-fatality rates concern rural districts and could  
400 be linked to health care access in these districts.

401 However, the increase in the standardized case-fatality rate due to exceptional  
402 situations during epidemic peaks represents less than 10% of the average case-fatality  
403 rate per district in France, and the hospital case-fatality rate without these districts  
404 would be reduced from 0.153 to 0.145. This increase cannot therefore explain the  
405 extent of the difference observed between the average case-fatality rate in France and  
406 the average of the rates reported for all countries by international organizations or  
407 information sites (WHO, Wordometer, etc.). These differences probably stem from the  
408 reporting of cases and deaths, which is uneven from one country to another, and not  
409 from the care or treatment of patients during hospital stress due to epidemic peaks.

## 410 References

- 411 [BAU 20] Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of  
412 mortality following COVID-19 infection. *Lancet Infect Dis*. 2020 (published online March  
413 12). [https://doi.org/10.1016/S1473-3099\(20\)30195-X](https://doi.org/10.1016/S1473-3099(20)30195-X)
- 414 [MIL 96] Miller RG. *Simultaneous Statistical Inference*. Springer Verlag, 1996.
- 415 [MOR 20] Morteza Abdullatif Khafaie, Fakher Rahim. Cross-Country Comparison of Case  
416 Fatality Rates of COVID-19/SARS-COV-2. *Osong Public Health and Research*  
417 *Perspectives* 2020; 11(2): 74-80.
- 418 [POR 08] Porta M. *A dictionary of Epidemiology*. 5th Ed. Oxford University Press, Oxford,  
419 2008.
- 420 [RIN 20] Gianluca Rinaldia , Matteo Paradisiba. An empirical estimate of the infection fatality  
421 rate of COVID-19 from the first Italian outbreak. Harvard Economics Department.
- 422 [ROQ 20] Roques L, Klein EK, Papaix J, Sar A. Using Early Data to Estimate the Actual  
423 Infection Fatality Ratio from COVID-19 in France. *Biology*, vol. 9, no 5, mai  
424 2020, p. 97 (DOI 10.3390/biology9050097)
- 425 [SAL 20] Henrik Salie, Cécile Tran-Kiem, Noémie Lefrancq, Noémie Courtejoie, Paolo  
426 Bosetti, et all. Estimating the burden of SARS-CoV-2 in France. 2020. *Science* 13 May  
427 2020. DOI: 10.1126/science.abc3517

- 428 [SOU 19] Souris M. Epidemiology and Geography. Principles, methods and tools of spatial  
429 analysis. Wiley-ISTE, London, 2019
- 430 [VER 20] Verity R, OKell L, Dorigatti L, & all. Estimates of the severity of coronavirus  
431 disease 2019: a model-based analysis. Lancet Infect Dis 2020, Published Online March  
432 30, 2020. [https://doi.org/10.1016/S1473-3099\(20\)30243-7](https://doi.org/10.1016/S1473-3099(20)30243-7)
- 433 [WHO 20] <https://covid19.who.int/>
- 434 [SPY 20] Spychalski P, Blazynska-Spychalska A, Kobiela J. Estimating case fatality rates  
435 of COVID-19. The Lancet, doi:[https://doi.org/10.1016/S1473-3099\(20\)30246-2](https://doi.org/10.1016/S1473-3099(20)30246-2)